Please assess the completion status of the following clinical trial:

Trial Title: Sorafenib vs.TransArterial Chemoembolization Plus RadioTherapy in Hepatocellular Carcinoma With Macrovascular Invasion

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2/PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age \>19 years~* Child-Pugh class A liver function~* Performance status: Eastern Cooperative Oncology Group (ECOG) score 0 or 1~* Hepatocellular carcinoma (HCC) confirmed by dynamic CT or MRI, or by biopsy~* HCC invasion of first or second branch portal vein or hepatic vein or inferior vena cava~* Reserved unilateral portal blood flow at least in partial~* HCC size larger than 1 cm and less than 50% of total liver volume~* No confirmed extrahepatic metastasis~* Adequate hematopoietic function Hemoglobin ≥ 8.5 g/dL Absolute neutrophil count ≥ 750/mm3 Platelet count ≥ 30,000/mm3~* Creatinine \< 1.5mg/dL~* No plan for pregnancy or breast feeding. Active contraception.~* Willing to give informed consent~Exclusion Criteria:~* Prior history to or exposure of transarterial chemoembolization, external beam radiation to liver, or sorafenib~* Complete obstruction of hepatic outflow~* Confirmed extrahepatic metastasis of HCC~* HCC occupying more than 50% of liver volume~* Uncontrolled ascites of hepatic encephalopathy~* Prior liver transplantation~* Positive for human immunodeficiency virus (HIV)~* Active gastric or duodenal ulcer~* Other uncontrolled comorbidities or malignancy~* Inability to give informed consent

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- TACE+External beam RT (Type: EXPERIMENTAL): Transarterial chemoembolization plus external beam radiation therapy
- Sorafenib (Type: ACTIVE_COMPARATOR): Sorafenib 800 mg/day orally

Based on this trial design, predict the completion outcome and termination type (if applicable).